Literature DB >> 11596647

Effects of dietary cholesterol restriction in a feline model of Niemann-Pick type C disease.

K L Somers1, D E Brown, R Fulton, P C Schultheiss, D Hamar, M O Smith, R Allison, H E Connally, C Just, T W Mitchell, D A Wenger, M A Thrall.   

Abstract

A feline model of Niemann-Pick disease type C (NPC) was employed to evaluate the effect of dietary cholesterol restriction on progression of disease. Two NPC-affected treated cats were fed a cholesterol-restricted diet beginning at 8 weeks of age; the cats remained on the diet for 150 and 270 days respectively. The study goal was to lower the amount of low density lipoprotein (LDL) available to cells, hypothetically reducing subsequent lysosomal accumulation of unesterified cholesterol and other lipids. Neurological progression of disease was not altered and dietary cholesterol restriction did not significantly decrease storage in NPC-affected treated cats. One NPC-affected treated cat had decreased serum alkaline phosphatase activity (ALP) and decreased serum cholesterol concentration. Liver lipid concentrations of unesterified cholesterol, cholesterol ester and phospholipids in NPC-affected treated cats were similar to those seen in NPC-affected untreated cats. Ganglioside concentrations in the NPC-affected treated cats and NPC-affected untreated cats were similar. Histological findings in liver sections from NPC-affected treated cats showed a diffuse uniform microvacuolar pattern within hepatocytes and Kupffer cells, in contrast to a heterogeneous macro/microvacuolar pattern and prominent nodular fibrosis in NPC-affected untreated cats. Similar differences in vacuolar patterns were seen in splenic macrophages. Although some hepatic parameters were modified, dietary cholesterol restriction did not appear to alter disease progression in NPC-affected kittens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11596647     DOI: 10.1023/a:1010588112003

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  31 in total

1.  GABAergic neuroaxonal dystrophy and other cytopathological alterations in feline Niemann-Pick disease type C.

Authors:  P A March; M A Thrall; D E Brown; T W Mitchell; A C Lowenthal; S U Walkley
Journal:  Acta Neuropathol       Date:  1997-08       Impact factor: 17.088

Review 2.  Gangliosides: structure, isolation, and analysis.

Authors:  R W Ledeen; R K Yu
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

3.  Mutations in NPC1 highlight a conserved NPC1-specific cysteine-rich domain.

Authors:  W L Greer; M J Dobson; G S Girouard; D M Byers; D C Riddell; P E Neumann
Journal:  Am J Hum Genet       Date:  1999-11       Impact factor: 11.025

4.  Niemann-Pick type-C disease: deficient intracellular transport of exogenously derived cholesterol.

Authors:  C F Roff; E Goldin; M E Comly; J Blanchette-Mackie; A Cooney; R O Brady; P G Pentchev
Journal:  Am J Med Genet       Date:  1992-02-15

5.  Complementation studies in human and feline Niemann-Pick type C disease.

Authors:  K L Somers; D A Wenger; M A Royals; E D Carstea; H E Connally; T Kelly; R Kimball; M A Thrall
Journal:  Mol Genet Metab       Date:  1999-02       Impact factor: 4.797

6.  Neurological manifestations of Niemann-Pick disease type C in cats.

Authors:  K R Muñana; P J Luttgen; M A Thrall; T W Mitchell; D A Wenger
Journal:  J Vet Intern Med       Date:  1994 Mar-Apr       Impact factor: 3.333

7.  Differential accumulation of cholesterol in Golgi compartments of normal and Niemann-Pick type C fibroblasts incubated with LDL: a cytochemical freeze-fracture study.

Authors:  R A Coxey; P G Pentchev; G Campbell; E J Blanchette-Mackie
Journal:  J Lipid Res       Date:  1993-07       Impact factor: 5.922

8.  The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C.

Authors:  M C Patterson; A M Di Bisceglie; J J Higgins; R B Abel; R Schiffmann; C C Parker; C E Argoff; R P Grewal; K Yu; P G Pentchev
Journal:  Neurology       Date:  1993-01       Impact factor: 9.910

9.  Alterations in cholesterol metabolism in cultured fibroblasts from patients with Niemann-Pick disease type C.

Authors:  C Mazière; J C Mazière; L Mora; A Lageron; C Polonovski; J Polonovski
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

10.  Marked heterogeneity in Niemann-Pick disease, type C. Clinical and ultrastructural findings.

Authors:  M R Natowicz; J M Stoler; E M Prence; L Liscum
Journal:  Clin Pediatr (Phila)       Date:  1995-04       Impact factor: 1.168

View more
  20 in total

Review 1.  The potential of histone deacetylase inhibitors in Niemann - Pick type C disease.

Authors:  Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  FEBS J       Date:  2013-09-23       Impact factor: 5.542

2.  Therapeutic potential of cyclodextrins in the treatment of Niemann-Pick type C disease.

Authors:  Benny Liu
Journal:  Clin Lipidol       Date:  2012-06

3.  2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease.

Authors:  Sarah Ward; Patricia O'Donnell; Steven Fernandez; Charles H Vite
Journal:  Pediatr Res       Date:  2010-07       Impact factor: 3.756

4.  Microarray expression analysis and identification of serum biomarkers for Niemann-Pick disease, type C1.

Authors:  Celine V M Cluzeau; Dawn E Watkins-Chow; Rao Fu; Bhavesh Borate; Nicole Yanjanin; Michelle K Dail; Cristin D Davidson; Steven U Walkley; Daniel S Ory; Christopher A Wassif; William J Pavan; Forbes D Porter
Journal:  Hum Mol Genet       Date:  2012-05-22       Impact factor: 6.150

5.  Niemann-Pick C1-deficient mice lacking sterol O-acyltransferase 2 have less hepatic cholesterol entrapment and improved liver function.

Authors:  Adam M Lopez; Ryan D Jones; Joyce J Repa; Stephen D Turley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-06-07       Impact factor: 4.052

6.  Dietary plant stanol ester supplementation reduces peripheral symptoms in a mouse model of Niemann-Pick type C1 disease.

Authors:  Inês Magro Dos Reis; Tom Houben; Yvonne Oligschläger; Leoni Bücken; Hellen Steinbusch; David Cassiman; Dieter Lütjohann; Marit Westerterp; Jos Prickaerts; Jogchum Plat; Ronit Shiri-Sverdlov
Journal:  J Lipid Res       Date:  2020-04-14       Impact factor: 5.922

Review 7.  Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.

Authors:  Paul Helquist; Frederick R Maxfield; Norbert L Wiech; Olaf Wiest
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 8.  Diagnostic workup and management of patients with suspected Niemann-Pick type C disease.

Authors:  Apostolos Papandreou; Paul Gissen
Journal:  Ther Adv Neurol Disord       Date:  2016-03-02       Impact factor: 6.570

9.  Niemann-Pick C1 functions in regulating lysosomal amine content.

Authors:  Allyn M Kaufmann; Jeffrey P Krise
Journal:  J Biol Chem       Date:  2008-06-30       Impact factor: 5.157

10.  Clinical, electrophysiological, and serum biochemical measures of progressive neurological and hepatic dysfunction in feline Niemann-Pick type C disease.

Authors:  Charles H Vite; Wenge Ding; Caroline Bryan; Patricia O'Donnell; Karyn Cullen; David Aleman; Mark E Haskins; Thomas Van Winkle
Journal:  Pediatr Res       Date:  2008-11       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.